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I
thank van der Staal et al. (1) for their
comments on our editorial (2). It is
gratifying, and not surprising, to hear
that hyperbaric oxygen therapy (HBOT),
like many other aspects of health care, is
less expensive in the Netherlands than in
theU.S.DatafromtheU.K.alsoshowthat
they can provide HBOT at a similar cost
(£40/session, 2006data)(3).Most hyper-
baric therapy for lower extremity wounds
in the U.S. is probably provided to pa-
tients who meet the Centers for Medicare
and Medicaid Services–deﬁned criteria,
i.e., a wound classiﬁed as Wagner grade
IIIorhigherthathasfailedtoimproveafter
at least 30 days of adequate standard
wound therapy. However, a Google search
forhyperbarictreatmentcentersfordiabetic
foot wounds reveals thousands of “hits”
from for-proﬁt centers that will, for a fee,
treat patients who may not meetthese strict
criteria. Not only does this lead many pa-
tients to waste money on unnecessary
(or certainly unproven) HBOT for their
wounds, it may delay them from receiving
other needed treatment, e.g., debridement,
pressure-ofﬂoading, antibiotic therapy, and
revascularization.
The authors state that HBOT in the
Netherlands“appear[s]tobecost-effective.”
Iwouldliketoseethedatathatsupportthis
assertion. Although Löndahl et al. (4) have
published follow-up analyses of their data
demonstratingthatHBOTimprovesquality
oflife,theyhavenotpresenteddataoncost-
effectiveness.One studyfoundthatadjunc-
tive HBOT produced an incremental cost
per quality-adjusted life-years at year 1 of
$27,310 and at year 12 of $2,255 (2001
values)(5).ArecentreportbytheCanadian
Agency for Drugs and Technologies in
HealthdidconcludethatHBOTfordiabetic
foot ulcers is cost-effective compared with
standard methods of care but pointed out
that even if seven-person HBOT chambers
were used, Canada would need up to an
additional 35 of these expensive machines
(nottomentionthestafftorunthem)(6).It
is also noteworthy that despite this ﬁnding,
adjunct HBOT is rarely used by Canadian
providers, largely because of inadequate
knowledge.
Although I agree that clinical evi-
dence is growing for the effectiveness of
HBOT in appropriately selected patients
with a diabetic foot ulcer, I think we need
moredataonitscost-effectiveness.I would
welcome such studies from various health
care systems.
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